Paliperidone Palmitate Injection（Ⅱ） (Luye Pharma)

棕榈酸帕利哌酮注射液（Ⅱ） (绿叶制药)

Report date: 2025/12/30 17:51:35

Base Information

Drug NamePaliperidone Palmitate Injection（Ⅱ） (Luye Pharma)
Drug Alias Name棕榈酸帕利哌酮缓释混悬注射液 (绿叶制药)(paliperidone palmitate) extended-release injectable suspension棕榈酸帕利哌酮注射液（LY03010）Paliperidone Palmitate Injection（Ⅱ）棕榈酸帕利哌酮注射液（长效针剂） +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsSedationSchizoaffective disorderSchizophrenia +[8] 
Global Approved IndicationsSchizoaffective disorderSchizophrenia
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryUnited States
Original Approved Date2024/07/26
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLuye Pharma Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLuye Innomind Pharma Shijiazhuang Co LtdLuye Pharma Group Ltd
Inactive CompaniesN/A
Active IndicationsSedationSchizoaffective disorderSchizophrenia +[7] 
Inactive IndicationsMental Disorders

Other Information

ATC CodeN/A
Related LinksN/A